

Hepatitis B virus core-related antigen is useful for surveillance of hepatocellular carcinoma recurrence in a patient with occult hepatitis B virus infection: Case report

Keiji Yokoyama¹, Eri Yamauchi¹, Yotaro Uchida¹, Takanori Kitaguchi¹, Hiromi Fukuda¹, Ryo Yamauchi¹, Naoaki Tsuchiya¹, Kaoru Umeda², Kazuhide Takata², Takashi Tanaka¹, Shinjiro Inomata¹, Daisuke Morihara¹, Yasuaki Takeyama¹, Satoshi Shakado¹, Shotaro Sakisaka², and Fumihito Hirai²

¹Fukuoka University

²Fukuoka University Faculty of Medicine

June 15, 2020

Abstract

A 73-year-old woman with occult hepatitis B virus (HBV) infection was diagnosed with hepatocellular carcinoma (HCC). Serum HBV core-related antigen (HBcrAg) was elevated and HBV covalently closed circular DNA (cccDNA) was presented in the liver tissue. This report shows HBcrAg might be a predictive factor for development of HCC.

Keywords

Hepatitis B core-related antigen, Hepatocellular carcinoma, Occult HBV infection

Key Clinical Message

Serum HBV core-related antigen (HBcrAg) is useful for detecting hepatocellular carcinoma (HCC) recurrence in patients with occult hepatitis B virus (HBV) infection. Surveillance for HCC is needed in patients in whom HBcrAg is positive, even if hepatitis B surface antigen (HBsAg) and HBV DNA are negative.

Introduction

It is estimated that 2 billion people worldwide have hepatitis B virus (HBV) infection, 350 million people have persistent HBV infection, and between 0.5 million and 1.2 million people die of HBV infection-related diseases annually.¹ Therefore, overcoming HBV is an important global issue. HBV is a risk factor for the development of hepatocellular carcinoma (HCC) and is one of the very important diseases from the viewpoint of not only treatment when HCC occurs but also prevention of carcinogenesis and recurrence.²

Patients with a positive test result for hepatitis B surface antigen (HBsAg) are often treated with a nucleic acid analog (NA) preparation for the suppression of progressing liver fibrosis and hepatocarcinogenesis. However, HBV DNA may be detected in serum or liver tissue in spite of a negative test result for serum HBsAg. These patients are considered as having occult HBV infection (OBI). OBI can also be a risk factor for hepatocarcinogenesis; therefore, it is important to detect it at an early stage. However, some patients with OBI have HBV DNA detectable in the blood, whereas others have HBV detectable only in the liver tissue. It may be difficult to detect OBI by means of normal surveillance.³ Patients with OBI are often found to have advanced HCC because they have not received HCC surveillance. We report a case of a patient with OBI in whom serum HBV core-related antigen (HBcrAg) was useful for the surveillance of HCC recurrence.

Case Report

A 73-year-old woman presented to our facility for follow-up. She had varicose veins in the right leg and no history of alcohol consumption or smoking. She had been found to be HBsAg-positive in the late 1980s and was attending a clinic. The HBV infection status of her mother was unknown. In June 2007, she was found to have HCC at segment 4 of the liver, and radiofrequency ablation (RFA) was performed. Laboratory investigation results at that time were as follows: HBsAg-positive, hepatitis B envelope antigen (HBeAg)-negative, hepatitis B envelope antibody (HBeAb)-positive, and HBV DNA titer of 2600 copies/mL. Two years later, her HBV DNA titer dropped below 2100 copies/mL. Another 2 y thereafter, her HBsAg became negative, and her HBV DNA became undetectable. She had no recurrence of HCC during this 4-year period; however, about 7 years after the initial treatment, a recurrence of HCC with a diameter of 18 mm was seen at segment 8 of the liver, and she was admitted to our department for HCC treatment. We ruled out the possibility of the recurrence being from local spread from segments 4 to 8 of the liver, because there had been no recurrence for 7 years and the new lesion was not in contact with the previous treatment site.

The patient had no significant symptoms on admission. Laboratory data on admission showed no abnormalities in blood count, coagulation system, general biochemical tests, and liver fibrosis markers. As for tumor markers, the patient's total α -fetoprotein (AFP) and des- γ -carboxy prothrombin (DCP) were normal, but her AFP-L3 fraction was as high as 43.9% (Table 1). Her virus markers were HBsAg-negative, HBeAg-negative, HbeAb-positive, and HBcAb-positive. Furthermore, her HBV DNA was not detectable at <2100 copies/mL, and her HBV core-related antigen (HBcrAg) was elevated at 3.7 log U/mL (normal value, < 3.0 log U/mL) (Table 2). Abdominal contrast-enhanced computed tomography (CT) revealed a high-low pattern tumor lesion having a diameter of 18 mm at segment 8 of the liver (Fig. 1a). In addition, abdominal contrast-enhanced magnetic resonance imaging (MRI) revealed that the patient's hepatic morphology was almost normal, and a high-low pattern was observed in dynamic imaging with a diameter of 18 mm in segment 8 of the liver. It was diagnosed as a neoplastic lesion because of its contrast-deficient appearance in the hepatocyte contrast phase. HCC recurrence was therefore diagnosed (Fig. 1b). Hepatic arteriography revealed a tumor stain from the anterior superior branch of the right hepatic artery (A8) (Fig. 2a). Transcatheter arterial chemoembolization (TACE) was performed from A8 using 50 mg of a cisplatin formulation for intravenous infusion (IA Coal®). After TACE, RFA was performed in a spherical shape with a diameter of 3 cm to surround the TACE area (Fig. 2b, c). Abdominal contrast CT after treatment confirmed that Lipiodol contrast agent (Guerbet, Princeton, NJ, USA) was well accumulated at the tumor site and that a sufficient ablation margin was secured (Fig. 3).

The patient was discharged after completing HCC treatment. She has been seen in follow-up for 5 years and has not shown any signs of recurrence. Her HBsAg has remained negative, and HBV DNA has not been detected; however, her HBcrAg has been slightly elevated. Currently, she is being monitored without any medication.

Discussion

In this case, although the patient's serum HBsAg and HBV DNA became negative after an initial treatment for HCC, she had tumor recurrence 7 y after treatment. The patient's clinical course from the initial occurrence of HCC is shown in Fig. 4. Her HBV DNA titer decreased to less than 2100 copies/mL from 2 years after the initial treatment; HBsAg became negative 4 years after the initial treatment; and HBV DNA became undetectable. Therefore, this case was assumed to be one of HCC recurrence after OBI. Upon admission, the patient's HBsAg was negative, and her HBV DNA was not detected. However, her HBcrAg was as high as 3.7 log U/mL. HBcrAg is known to correlate with the amount of covalently closed circular DNA (cccDNA) in hepatocytes, and it has been reported that HBcrAg may be useful as a criterion for stopping NA preparations.^{4, 5} In addition, its usefulness in predicting HCC occurrence and recurrence with the use of NA has been reported.⁶ In this case, on the basis of nontumor liver biopsy performed during RFA, quantitative measurement of HBV cccDNA revealed 1.8 log copies/ μ g in liver tissue. It is known that HBV DNA is present in liver tissue at a high rate even if serum HBV DNA is negative.⁷ Therefore, our patient's case was confirmed to be OBI.

The association of OBI with hepatocarcinogenesis has been reported.^{3, 8–10} In an analysis of 53 HBsAg-negative patients with unexplained HCC, Wong et al reported that cccDNA was detected in liver tissue of 29 (47%) patients.¹¹ On the basis of these reports, it was presumed that our patient also likely developed carcinogenesis from OBI. The scheme for HBV infection and the pathway of hepatocarcinogenesis is shown in Fig. 5. Two major pathways are considered for hepatocellular carcinogenesis. The first is through accumulation of hepatocellular DNA damage due to oxidative stress during the progression of chronic inflammation and fibrosis.^{12–15} The second is through a direct carcinogenesis mechanism by HBV; that is, HBx protein and HBV DNA activate transcription factors such as nuclear factor- κ B and promote the production of cytokines such as tumor necrosis factor- α and interleukin-6 by incorporation into the cell genome, thereby affecting cell proliferation and apoptosis.^{16–19} Our patient had few chronic inflammatory changes in liver morphology, and her hepatobiliary enzymes and liver fibrosis markers were normal. Therefore, it is considered that the direct carcinogenic mechanism of HBV is more likely to be the trigger for her hepatocarcinogenesis. There are several reports on the inhibitory effect of NA on hepatocarcinogenesis in chronic hepatitis B.^{2, 20} However, there is no clear evidence of whether hepatic carcinogenesis can be suppressed by administering NA in patients with only a high HBcrAg. Our patient was seen in follow-up without any medication (with her consent), and she has been recurrence-free for about 5 y. However, it is necessary to continue careful follow-up, considering her history of HCC recurrence 7 y after her first case. Currently, several drugs that eliminate HBV cccDNA in hepatocytes are being developed,^{21–24} and it is strongly hoped that such drugs will soon be approved for clinical use in the near future.

In conclusion, HBcrAg is useful for detecting HCC recurrence in patients with OBI. Surveillance for HCC is needed in patients in whom serum HBcrAg is positive, even if HBsAg and HBV DNA are negative.

Conflict of Interest

The authors have no conflicts of interest to declare.

Author Contributions

All authors participated in data collection. KY contributed to the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Editage (www.editage.com) for English language editing. We also express our gratitude to Waki Nagashima, Yuki Nozaki, Atsuko Ishibashi, Nao Kodama, Rina Akahoshi, Chihiro Tanaka, Akiko Tanaka, Motoko Kawashima, and Tomoko Nagaura for their invaluable support.

References

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat.* 2004;11:97–107.
2. Liaw YF, Sung JJ, Chow WC, et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med.* 2004;351:1521–1531.
3. Muto J, Sugiyama M, Shirabe K, et al. Frequency and characteristics of occult hepatitis B infection among hepatocellular carcinoma patients in Japan. *Ann Hepatol.* 2018;17:596–603.
4. Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. *J Med Virol.* 2009;81:27–33.
5. Matsumoto A, Tanaka E, Minami M, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. *Hepatol Res.* 2007;37:661–666.
6. Hosaka T, Suzuki F, Kobayashi M, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. *Liver Int.* 2010;30:1461–1470.
7. Hu KQ. Occult hepatitis B virus infection and its clinical implications. *J Viral Hepatol.* 2002;9:243–257.

8. Ohba K, Kubo S, Tamori A, et al. Previous or occult hepatitis B virus infection in hepatitis surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma. *Surg Today*. 2004;34:842–848
9. Makvandi M. Update on occult hepatitis B virus infection. *World J Gastroenterol*. 2016;22(39):8720–8734.
10. Sosa-Jurado F, Meléndez-Mena D, Rosas-Murrieta NH, et al. Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients. *PLoS One*. 2018;13:e0205356.
11. Wong DK, Cheng SCY, Mak LL, et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. *Clin Gastroenterol Hepatol*. 2020;18:449–456.
12. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*. 2006; 295:65–73.
13. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. *Gastroenterology*. 2012;142:1140–1149.
14. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet*. 2009;41:591–595.
15. Kumar V, Lo PHY, Sawa H, et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. *PLoS One*. 2012;7:e44743.
16. Patrini P, Poussin K, Kew M, et al. Selective accumulation of the X transcription of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. *Hepatology*. 1995;21:313–321.
17. Bréchot C. Pathogenesis of hepatitis B virus -related hepatocellular carcinoma: Old and new paradigms. *Gastroenterology*. 2004;127:S56–S61.
18. Jiang J, Gusev Y, Aderca , et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. *Clin Cancer Res*. 2008;14:419–27.
19. Sartorius K, Makarova J, Sartorius B, et al. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis. *Cells*. 2019;8:1504.
20. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology*. 2013;58:98–107.
21. Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas 9 system facilitates clearance of the intrahepatic HBV templates in vivo. *Mol Ther Nucleic Acids*. 2014;3:e186.
22. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. *Mol Ther Nucleic Acids*. 2014;3:e216.
23. Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. *Nat Rev Drug Discov*. 2019;18:827–844.
24. Sekiba K, Otsuka M, Ohno M, et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. *Hepatology*. 2019;69:1903–1915.

Figure legends

Fig. 1 (a) Abdominal contrast-enhanced computed tomographic scan in early phase. Liver morphology is almost normal with no splenomegaly. A high–low pattern lesion with a diameter of 18 mm was observed in segment 8 of the liver (*arrow*); therefore, hepatocellular carcinoma (HCC) recurrence was diagnosed. **(b)** Abdominal contrast-enhanced magnetic resonance imaging scan in hepatobiliary phase. The hepatic morphology was almost normal. A high–low pattern was observed in dynamic imaging with a diameter of 18 mm in segment 8 of the liver, and a neoplastic lesion that was a contrast-deficient image in the hepatocyte contrast phase was recognized (*arrow*), confirming HCC recurrence.

Fig. 2 (a) Abdominal angiographic findings. In hepatic arteriography, a tumor stain was observed from the anterior superior branch of right hepatic artery 8 (*arrow*). **(b, c)** Radiofrequency ablation was performed in a spherical shape with a diameter of 3 cm to surround the transarterial chemoembolization area (*arrows*).

Fig. 3 Abdominal contrast-enhanced computed tomography after treatment confirmed that Lipiodol was well accumulated at the tumor embolus and a sufficient ablation margin was secured (*arrows*).

Fig. 4 The clinical course of hepatocellular carcinoma (HCC) in this case. In June 2007, the patient was found to have HCC occurrence, and radiofrequency ablation (RFA) was performed. Two years later, the patient's hepatitis B virus (HBV) DNA titer dropped below 2100 copies/mL. Another 2 y later, her hepatitis B surface antigen (HBsAg) became negative, and her HBV DNA became undetectable. However, about 7 y after the initial treatment, a recurrence of HCC was seen in the liver.

Fig. 5 The scheme for hepatitis B virus (HBV) infection and the pathway of hepatocellular carcinoma (HCC) carcinogenesis.

Fig. 1




Fig. 2




Fig. 3



Fig. 4




Fig. 5

